Active, not recruitingPhase 2NCT07471880
A Phase II Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral Head
Studying Idiopathic avascular necrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.
- Intervention
- RAB001 high dose(drug)
- Enrollment
- 161 enrolled
- Eligibility
- 18-69 years · All sexes
- Timeline
- 2024 – 2027
Study locations (1)
- ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd., Zhongshan, Guangdong, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07471880 on ClinicalTrials.govOther trials for Idiopathic avascular necrosis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT03357445AVANTAGE® RELOAD Double Mobility Acetabular Cup -Clinical StudyZimmer Biomet
- ACTIVE NOT RECRUITINGNANCT01458782ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the KneeUniversity Hospital of North Norway
- RECRUITINGNCT05603728Exactech Shoulder Post Market Clinical Follow-up StudyExactech